MOTS-c — Complete Research Guide (2026)

Last updated 2026-06-25

What is MOTS-c?

MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region, first characterized by Changhan Lee, Pinchas Cohen and colleagues. It is studied for insulin sensitivity, metabolism, and exercise/physical performance, but it is an investigational research peptide and is not approved by the FDA, EMA, or any major regulator for any indication.

The mechanistic and efficacy evidence is predominantly preclinical (mouse and cell studies), supplemented by human association studies (e.g., exercise-induced expression and fat-distribution correlations) rather than controlled clinical trials.

How does MOTS-c work?

In muscle and cell models MOTS-c inhibits the folate-purine biosynthesis cycle, raising AICAR and activating AMPK, which promotes glucose uptake (GLUT4) and fatty-acid oxidation.

It can also translocate to the nucleus to influence stress-response gene expression, but these mechanisms are chiefly demonstrated in animals and cells. [INFOGRAPHIC: MOTS-c AMPK activation and metabolism]

What does the research say about MOTS-c?

• In mice, MOTS-c improved insulin sensitivity and prevented diet-induced obesity and age-related insulin resistance, acting largely through AMPK activation in skeletal muscle. ^[1]
• In aged mice, intermittent MOTS-c injections increased running capacity and physical performance; in humans, exercise raised endogenous MOTS-c (an association, not a treatment effect). ^[2]
• In people without diabetes, higher plasma MOTS-c was associated with android and liver fat, an observational human correlation, not evidence that dosing MOTS-c changes body fat. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

• [1] The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance — Lee C et al., Cell Metab 2015. (animal (mice) + human plasma)
• [2] MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis — Reynolds JC et al., Nat Commun 2021. (animal + human exercise association)
• [3] The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity — Kim SJ et al., Physiol Rep 2019. (animal (mice))
• [4] Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes — Sequeira IR et al., Biochim Biophys Acta Gen Subj 2021. (human association)
• [5] Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration — Kumagai H et al., Am J Physiol Endocrinol Metab 2024. (animal (mice))

Dosing context

Dosing figures in the literature (e.g., intraperitoneal regimens several times weekly) come from mouse experiments and do not translate to a validated human dose.

This information is provided for research context only and is not a dosing recommendation.

Side effects & safety profile

There are no controlled human clinical safety trials of administered MOTS-c; nearly all interventional data come from rodent and cell studies, while human data are limited to observational measurements of endogenous levels.

Because the human work is associational, it cannot establish the safety (or efficacy) of injecting supraphysiologic MOTS-c.

No validated human pharmacokinetic profile or half-life is established, and this content does not endorse human use.

Stacking & combinations

MOTS-c is often discussed together with exercise and other mitochondrial-derived peptides in metabolic research, but no controlled human study validates any specific combination for efficacy or safety.

Finding MOTS-c vendors

User reviews

Frequently asked questions

References

1. [1] The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance — Lee C et al., Cell Metab 2015. PMID: 25738459. View sourceStudy: animal (mice) + human plasmaMOTS-c activated AMPK, improved insulin sensitivity and prevented diet-induced and age-related metabolic dysfunction in mice; also detectable in human plasma and declines with age.
2. [2] MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis — Reynolds JC et al., Nat Commun 2021. PMID: 33473109. View sourceStudy: animal + human exercise associationMOTS-c treatment increased physical capacity and healthspan in aged mice; exercise induced endogenous MOTS-c in human skeletal muscle and circulation.
3. [3] The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity — Kim SJ et al., Physiol Rep 2019. PMID: 31293078. View sourceStudy: animal (mice)In diet-induced obese mice, MOTS-c altered lipid/metabolite pathways and enhanced insulin sensitivity.
4. [4] Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes — Sequeira IR et al., Biochim Biophys Acta Gen Subj 2021. PMID: 34419510. View sourceStudy: human associationCirculating MOTS-c correlated with android and liver fat depots in non-diabetic participants.
5. [5] Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration — Kumagai H et al., Am J Physiol Endocrinol Metab 2024. PMID: 38170165. View sourceStudy: animal (mice)MOTS-c reduced disuse muscle atrophy and lipid infiltration via AKT/FOXO signaling in mice.

Related peptides